NuPathe Files for IPO
NuPathe Inc., a Conshohocken, Penn.-based drug developer focused on the central nervous system, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol PATH, with Lazard Capital Markets and Leerink Swann serving as co-lead underwriters. The company reports $11.3 million in 2009 revenue and a $15.6 million net loss. NuPathe has raised $53 million in VC funding, from firms like Quaker BioVentures, Safeguard Scientifics, Battelle Ventures, Birchmere Ventures, S.R. One Ltd. www.nupathe.com
14 May 2010•1 min read
